Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-05-27FDA Approved: LEVETIRACETAM — Original Application (ScieGen Pharmaceuticals, Inc.)
The FDA approved an original Abbreviated New Drug Application (ANDA) for Levetiracetam from ScieGen Pharmaceuticals, establishing a generic …
-
FDA approval · 2022-05-27FDA Approved: LEVETIRACETAM — Original Application (Ascend Laboratories, LLC)
FDA approved a generic formulation of levetiracetam under an original application by Ascend Laboratories, LLC.
-
FDA approval · 2022-05-25FDA Approved: ZONISAMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for zonisamide from Sun Pharmaceutical Industries, expanding the use or labeling of the product.…
-
FDA approval · 2022-05-25FDA Approved: ZONISAMIDE — Supplemental Application (Exelan Pharmaceuticals, Inc.)
FDA approved a supplemental application for Zonisamide from Exelan Pharmaceuticals, Inc., approving changes to the approved generic product …
-
FDA label_change · 2022-05-25FDA Approved: ZONISAMIDE — Supplemental Application (Viona Pharmaceuticals Inc)
The FDA approved a supplemental application for Zonisamide from Viona Pharmaceuticals Inc, resulting in changes to the product label.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-05-25FDA Approved: ZONISAMIDE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for Zonisamide from BluePoint Laboratories (ANDA 077651).
-
FDA approval · 2022-05-19FDA Approved: LACOSAMIDE ORAL SOLUTION — Original Application (Ascend Laboratories, LLC)
The FDA approved an ANDA for lacosamide oral solution from Ascend Laboratories, LLC. This generic formulation is intended for use in treatin…
-
FDA approval · 2022-05-03FDA Approved: LACOSAMIDE — Original Application (Fresenius Kabi USA, LLC)
The FDA approved Fresenius Kabi USA, LLC's original application for lacosamide (ANDA214677), allowing the marketing of a generic lacosamide …
-
EMA withdrawal · 2022-04-26EMA Withdrawn: Pregabalin Mylan Pharma (pregabalin) — Mylan S.A.S.
EMA withdrawal notice for pregabalin marketed by Mylan S.A.S., affecting anxiety disorders, neuralgia, and epilepsy indications.
-
FDA approval · 2022-04-07FDA Approved: LACOSAMIDE — Original Application (Sagent Pharmaceuticals)
FDA approved Sagent Pharmaceuticals' original application for lacosamide (generic), enabling marketing of a generic lacosamide product for s…
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Safety of Autologous MSC Infusion to Treat Epilepsy [Phase 1, Phase 2]
Clinical trial update on the safety of autologous mesenchymal stem cell infusion for epilepsy (Phase 1/Phase 2 completed).
-
FDA approval · 2022-03-31FDA Approved: GABAPENTIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for gabapentin from Ascend Laboratories, LLC.
-
FDA approval · 2022-03-31FDA Approved: LACOSAMIDE — Original Application (Ascend Laboratories, LLC)
FDA approved lacosamide as a generic product from Ascend Laboratories under an Original Application (ANDA 214695). Lacosamide is indicated f…
-
FDA approval · 2022-03-31FDA Approved: CARBAMAZEPINE ER — Original Application (Bostal LLC)
FDA approved Bostal LLC's original-application generic extended-release carbamazepine (CARBAMAZEPINE ER), marking the first approval of this…
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: Effect of Pyridoxine on Behavioral Adverse Events of Levetiracetam [Phase 4]
Phase 4 trial updates the effect of pyridoxine on behavioral adverse events associated with levetiracetam in epilepsy.
-
FDA approval · 2022-03-28FDA Approved: LEVETIRACETAM — Original Application (Solco Healthcare US, LLC)
FDA approves Solco Healthcare US, LLC's generic levetiracetam through an Original Application (ANDA). The approval covers the same epilepsy …
-
FDA approval · 2022-03-24FDA Approved: CLOBAZAM — Original Application (Aurobindo Pharma Limited)
FDA approved an original ANDA for CLOBAZAM (clobazam) by Aurobindo Pharma Limited. It is a generic treatment for seizures associated with Le…
-
CLINICAL_TRIALS trial_result · 2022-03-22Clinical Trial Update: Lacosamide in Neonatal Status Epilepticus [Phase 3]
Phase 3 clinical trial update for lacosamide in neonatal status epilepticus; current status is unknown.
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's Original Application for a generic lacosamide product, enabling its marketing as an anticonvulsant for par…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved the original application (ANDA) for lacosamide as a generic product by Alembic Pharmaceuticals Inc., enabling its marketing as …
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' lacosamide as an original application (ANDA) generic product. This marks the availability of a gene…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (ScieGen Pharmaceuticals Inc)
FDA approved ScieGen Pharmaceuticals Inc's lacosamide generic under an Original Application (ANDA205237) for marketing in epilepsy patients.…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (MSN LABORATORIES PRIVATE LIMITED)
FDA approved MSN Laboratories' original application for lacosamide as a generic anticonvulsant under an ANDA, expanding access to lacosamide…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Glenmark Pharmaceuticals Inc. USA)
The FDA approved Glenmark’s lacosamide as an original generic drug application (ANDA); lacosamide is an anticonvulsant used to treat partial…
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Tris Pharma Inc)
FDA approved lacosamide from Tris Pharma Inc as an original generic drug application (ANDA 208308).